Buffett vs. Woodford: Who’s Winning on Tesco PLC (TSCO)?

Page 1 of 2

LONDON — This time last year, Warren Buffett, the famous billionaire U.S. investor, and Neil Woodford, the ace U.K. fund manager, took polarized positions on the investment case for top FTSE 100 supermarket Tesco PLC (LON:TSCO).

Tesco had just issued its first profit warning in 20 years. Woodford was a seller. Buffett was a buyer. Rarely have two such renowned investors been effectively at the opposite ends of the same trade.

One year on, which of these two master investors currently looks to have made the right call?

Buffett buys big
In the wake of Tesco’s profit warning, Buffett acquired an interest in more than 150 million shares, increasing his stake in the company from 3.2% to 5.1%. Buffett did the trade by entering into a somewhat complex equity-swap deal. I’m going to take an average of the prevailing prices at the time — a round-figure number of 320 pence — and use that value to judge his performance. At last week’s closing price of 350 pence, Buffett is 9% up on the trade.

Elan Corporation, plc (ADR) (NYSE:ELN)

Woodford spreads his bets
Was Woodford wrong to sell Tesco? Well, that rather depends on what he bought in its place. In the report of his Invesco Perpetual High Income fund covering Jan. 1 to June 30, 2012, Woodford told us:

There was relatively little trading activity during the period. The fund sold its holding in International Power plc (LON:IPR) … and sold its holding in Tesco. … It increased its holding in Capita PLC (LON:CPI) and also added to holdings in health care companies Elan Corporation, plc (NYSE:ELN), Sanofi SA (NYSE:SNY) and Smith & Nephew plc (NYSE:SNN).

I’ve summarized Woodford’s buys, the prices I calculate he bought at, and the returns to date in the table below.

Company Investment (millions of pounds) Buy Price per Share Share Price as of Jan. 18 Gain/Loss
Smith & Nephew 130 622 pence 697 pence 12%
Sanofi 108 57 euros 72 euros 26%
Elan 56 $14 $10 (29%)
Capita 55 662 pence 798 pence 21%
Total weighted return 11%

There’s not much in it, then, after one year: Buffett is up 9% on Tesco, but Woodford is slightly ahead with a weighted gain of 11% — even though Elan has let him down badly so far.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!